openPR Logo
Press release

Leiomyosarcoma Pipeline | Clinical Trials, Key Companies- Merck, PTC Therapeutics

11-06-2023 12:45 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Leiomyosarcoma Pipeline

Leiomyosarcoma Pipeline

DelveInsight's, "Leiomyosarcoma - Pipeline Insight, 2023," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download Sample Report to learn more @https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Leiomyosarcoma Overview
Leiomyosarcoma is a type of rare cancer that grows in the smooth muscles. The smooth muscles are in the hollow organs of the body, including the intestines, stomach, bladder, and blood vessels. In females, there is also smooth muscle in the uterus. These smooth muscle tissues help move blood, food, and other material through the body and work without you being aware. Leiomyosarcoma is an aggressive cancer, which means it can grow quickly.

Click here to learn more about the Leiomyosarcoma Market Landscape @https://www.delveinsight.com/report-store/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlight from Leiomyosarcoma Pipeline Report
The Key Companies working in Leiomyosarcoma include Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, and many others.
The Key Therapies included in Leiomyosarcoma include ADI PEG20, AL-3818, and many others.

Major Players in Leiomyosarcoma
There are approx. 10+ key companies that are developing therapies for Leiomyosarcoma. The companies that have their Leiomyosarcoma drug candidates in the most advanced stage, i.e. phase III include Advenchen Laboratories.
Phases

DelveInsight's Report covers around 10+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates

Route of Administration
Leiomyosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Learn more about the treatment market for Leiomyosarcoma @ https://www.delveinsight.com/report-store/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
Key Insights
Leiomyosarcoma Introduction
Executive Summary of Leiomyosarcoma
Disease Background and Overview
Leiomyosarcoma Epidemiology and patient population
Leiomyosarcoma Emerging Therapies
Leiomyosarcoma Market Outlook
Leiomyosarcoma Market Access and Reimbursement of Therapies
Leiomyosarcoma Market Drivers
Leiomyosarcoma Market Barriers
Appendix
Leiomyosarcoma Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Leiomyosarcoma Market Outlook report @
https://www.delveinsight.com/report-store/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Leiomyosarcoma Pipeline | Clinical Trials, Key Companies- Merck, PTC Therapeutics here

News-ID: 3277264 • Views:

More Releases from DelveInsight Business Research LLP

RNA Interference Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
RNA Interference Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EM …
DelveInsight's "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment
Amyotrophic Lateral Sclerosis Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Amyotrophic Lateral Sclerosis Pipeline Drugs Insights Report 2025: Clinical Tria …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Amyotrophic
NK Cell Therapy Pipeline Outlook Report 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
NK Cell Therapy Pipeline Outlook Report 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapies pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the
TCR Therapy Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
TCR Therapy Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA …
DelveInsight's "TCR Therapy Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TCR Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment

All 5 Releases


More Releases for Leiomyosarcoma

Uterine Leiomyosarcoma Market is expected to reach USD 1.2 billion by 2034
Uterine leiomyosarcoma (uLMS) is a rare but highly aggressive subtype of soft tissue sarcoma that originates in the smooth muscle layer of the uterus. Unlike benign fibroids, uLMS is often diagnosed at advanced stages and is associated with poor prognosis, high recurrence rates, and limited treatment options. Representing less than 1% of all uterine cancers, it nevertheless accounts for a disproportionate share of mortality in gynecologic oncology. Download Full PDF Sample
Leiomyosarcoma Drug Market Estimated to Experience a Hike in Growth by 2033
The Leiomyosarcoma Drug Market was valued at USD 0.72 billion in 2023, and it is projected to reach USD 1.55 billion by 2033, growing at a CAGR of 8.0% from 2024 to 2033. Leiomyosarcoma Drug Market Overview The Leiomyosarcoma Drug Market is expanding due to the increasing prevalence of soft tissue sarcomas and advancements in oncology therapeutics. Leiomyosarcoma, a rare but aggressive cancer, has driven demand for more effective and targeted treatments.
Leiomyosarcoma Treatment Market Thrives with Strong Growth Prospects During 2024 …
A new report published by CoherentMI, titled "Leiomyosarcoma Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Leiomyosarcoma Treatment market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The leiomyosarcoma treatment market is estimated to be valued at USD 1.3 billion in 2024 and is expected to reach USD 2.4
Leiomyosarcoma Clinical Trials, Treatment Drugs, Emerging Drugs, and Companies 2 …
DelveInsight's, "Leiomyosarcoma Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Leiomyosarcoma Pipeline. Dive
Leiomyosarcoma Treatment Market is expected to reach USD 834.12 million by 2030
Global leiomyosarcoma treatment market has experienced significant growth due to the increased prevalence of soft tissue sarcomas is one of the driving factors for the global leiomyosarcoma treatment market. For instance, in the U.S., total new cases diagnosed for soft tissue sarcomas are 13,460 and 5,350 people which are expected to die from this type of cancer. Increase in women population having fibroids may have the chances to develop LMS
Leiomyosarcoma Pipeline Booms as 10+ Therapies Likely to Enter the Treatment Dom …
DelveInsight's, "Leiomyosarcoma Pipeline Insight, 2023," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Leiomyosarcoma pipeline landscape. It covers the Leiomyosarcoma pipeline drug profiles, including Leiomyosarcoma clinical trials and nonclinical stage products. It also covers the Leiomyosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. For Leiomyosarcoma emerging drugs, the Leiomyosarcoma